Tag Archives: ReNetX Bio

ReNetX Bio, Inc. Announces U.S. FDA Authorization to Proceed for IND Application to Treat Patients with Chronic Spinal Cord Injury

NEW HAVEN, Conn.,¬†June 19, 2019¬†/PRNewswire/ — ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system disorders, has announced that the U.S. Food and Drug Administration (FDA) has allowed the … Continue reading

Posted in Chronic Spinal Cord Injury Research, spinal cord injury research | Tagged | 2 Comments

Two Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board

NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) — ReNetX Bio, a company developing first-in-class therapeutics to treat injury to the central nervous system, is expanding its Scientific Advisory Board with key opinion leaders specializing in spinal cord injury. ReNetX … Continue reading

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research | Tagged , ,